JP2021535209A5 - - Google Patents

Info

Publication number
JP2021535209A5
JP2021535209A5 JP2021534405A JP2021534405A JP2021535209A5 JP 2021535209 A5 JP2021535209 A5 JP 2021535209A5 JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021535209 A5 JP2021535209 A5 JP 2021535209A5
Authority
JP
Japan
Prior art keywords
formula
peptide compound
seq
use according
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535209A (ja
JP7592320B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051170 external-priority patent/WO2020037434A1/en
Publication of JP2021535209A publication Critical patent/JP2021535209A/ja
Publication of JP2021535209A5 publication Critical patent/JP2021535209A5/ja
Application granted granted Critical
Publication of JP7592320B2 publication Critical patent/JP7592320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534405A 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 Active JP7592320B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US62/722,726 2018-08-24
US201962804063P 2019-02-11 2019-02-11
US62/804,063 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (3)

Publication Number Publication Date
JP2021535209A JP2021535209A (ja) 2021-12-16
JP2021535209A5 true JP2021535209A5 (cg-RX-API-DMAC7.html) 2022-08-29
JP7592320B2 JP7592320B2 (ja) 2024-12-02

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534405A Active JP7592320B2 (ja) 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物

Country Status (8)

Country Link
US (1) US20220000971A1 (cg-RX-API-DMAC7.html)
EP (1) EP3844190A4 (cg-RX-API-DMAC7.html)
JP (1) JP7592320B2 (cg-RX-API-DMAC7.html)
CN (1) CN113286820B (cg-RX-API-DMAC7.html)
AU (1) AU2019324747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3110414A1 (cg-RX-API-DMAC7.html)
IL (1) IL281043A (cg-RX-API-DMAC7.html)
WO (1) WO2020037434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
PT3380495T (pt) * 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CN117320756A (zh) * 2021-02-26 2023-12-29 特拉斯福特普拉斯公司 用于靶向癌干细胞的方法和结合分拣蛋白的缀合化合物
CA3208147A1 (en) * 2021-02-26 2022-09-01 Richard Beliveau Methods and compounds for targeting cancer stem cells
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
WO2024103161A1 (en) * 2022-11-14 2024-05-23 Theratechnologies Inc. Drug conjugate compounds for stimulating the antitumor immune response
CN122249236A (zh) * 2023-09-11 2026-06-19 瑟瑞技术公司 喜树碱类似物的肽缀合物及其用途
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
TW202604936A (zh) * 2024-07-25 2026-02-01 大陸商上海湃鴻生物科技有限公司 一種多肽藥物偶聯物及其製備方法和應用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302488B1 (en) * 2015-06-03 2020-09-30 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
PT3380495T (pt) * 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores

Similar Documents

Publication Publication Date Title
JP2019501141A5 (cg-RX-API-DMAC7.html)
ES2882634T3 (es) Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
JP7592320B2 (ja) ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物
CN102762586B (zh) 治疗肽
CN101501060B (zh) 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽
CN106132959B (zh) 用于缀合的细胞毒性微管溶素化合物
CN112386707B (zh) 一种肿瘤靶向多肽药物偶联物及其制备方法
CA3067311A1 (en) Cd38 antibody drug conjugate
CN103044521B (zh) 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途
CN103732238A (zh) 用于免疫调节的治疗性化合物
JP2020508985A5 (cg-RX-API-DMAC7.html)
ITMI20100093A1 (it) Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP2023505298A5 (cg-RX-API-DMAC7.html)
JP2012505922A5 (cg-RX-API-DMAC7.html)
CN102036676A (zh) 新颖的双重靶向性抗肿瘤轭合物
BG65926B1 (bg) Кахалалидни съединения
JP2019535702A (ja) ジンセンチド及びジンセンチド様ペプチドの調製及び使用
TR201807811T4 (tr) Bileşikler.
US20200247842A1 (en) Immune-stimulating soluble doxorubicin-conjugated complex
KR20230167033A (ko) 암 줄기 세포를 표적화하기 위한 방법 및 소르틸린 결합 접합체 화합물
CN104910280A (zh) 一种融合多肽及其在制备抗肿瘤药物中的应用
US20190015519A1 (en) Mmp-sensitive taxane prodrug
CN107857800B (zh) 一种长效整合素抑制剂及其应用
CN102875651B (zh) 抗肿瘤靶向激活的多肽阿霉素、其制备方法和用途